Common glaucoma drug reduces risk of vision loss

By: Agencies | | Updated: March 5, 2016 8:34 pm

डोळे हा मानवी शरीरातील एक महत्त्वाचे ज्ञानेंद्रियं ! पण त्याचे आरोग्य राखण्यासाठी आपण फारसे प्रयत्न करत नाही. मग आहारातच काही पदार्थांचा समावेश करा आणि डोळ्यांचे आरोग्य वाढवा.

London, Dec 19: A pressure-lowering eye drop has been found to greatly reduce the risk of vision loss in people with open angle glaucoma (OAG), one of the leading causes of blindness. The trial to assess the vision-preserving effect of prostaglandin analogue eye drop, which is already in common use for treatment of glaucoma, confirmed its efficacy. Also Read - Solar eclipse: Is it OK to look at the sun during the eclipse through an X-ray film?

Also Read - Solar Eclipse 2020: Health myths to shun and safety measures for viewing the ring of fire

‘Our findings offer solid proof to patients and practitioners that the visual deterioration caused by glaucoma can be reduced using this treatment,’ said lead author David Garway-Heath from UCL (University College London) Institute of Ophthalmology. OAG currently affects around 45 million people worldwide. Vision loss from glaucoma occurs when the optic nerve is damaged. In most cases, increased pressure inside the eye (intraocular pressure), is thought to contribute to this damage. (Read: Coming soon personalised gene therapies for vision loss) Also Read - 7 reasons why the #BeefBan is good

‘Medication to lower raised eye pressure has been used for decades as the main treatment for OAG to delay progressive vision loss,’ Garway-Heath explained. ‘But, until now, the extent to which the most frequently prescribed class of pressure-lowering drugs (prostaglandin analogues) have a protective effect on vision was not known,’ Garway-Heath added. (Read: Coming soon personalised gene therapies for vision loss) Read more about Are there any home remedies to improve eyesight?

The study recruited 516 newly diagnosed, previously untreated individuals with OAG in Britain. Half were randomly assigned to daily pressure-lowering eye drops and the other half to a matching placebo. The risk of visual deterioration was over 50 percent lower in the group treated with daily pressure-lowering eye drops compared to those using placebo drops over 2 years. The study was published in the journal The Lancet. (Read: )

Source: IANS

Photo source: Getty images

Published : December 19, 2014 7:37 pm | Updated:March 5, 2016 8:34 pm

Read Disclaimer